Feb 10, 2026 7:00 am EST Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Jan 21, 2026 11:18 pm EST Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
Jan 12, 2026 7:00 am EST Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
Dec 3, 2025 8:01 pm EST Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)